Sector & Market
Oral GLP-1 Obesity Drugs See Early Adoption
Bernstein survey of 25 U.S. providers across 14 states finds oral GLP-1s account for ≤10% of new weekly obesity prescriptions.
Providers expect oral GLP-1s to expand patient pool, not replace injectab
